Kobayashi Katsuhiko, Oguchi Tomohiro, Asamura Kenji, Miyagawa Maiko, Horai Satoshi, Abe Satoko, Usami Shin-ichi
Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
Auris Nasus Larynx. 2005 Jun;32(2):119-24. doi: 10.1016/j.anl.2005.01.010. Epub 2005 Mar 24.
To examine the frequency of the 961delT mitochondrial point mutation, considered to be associated with aminoglycoside-induced hearing loss, restriction fragment length polymorphism (RFLP) analysis was performed in (1) 334 unrelated sensorineural hearing loss (SNHL) patients and (2) 56 patients with aminoglycoside antibiotic injection history. Approximately 2% of the SNHL patients had the 961delT mutation, raising the possibility of a relatively high prevalence of this mutation among hearing impaired populations. However, the following findings cast doubt on whether this mutation is truly associated with hearing loss: (1) a similar frequency found in the control subjects, (2) hearing loss that was not segregated within the families, (3) rates of heteroplasmy and aging that were not correlated with the severity of hearing loss, and (4) a low prevalence among the aminoglycoside-induced hearing loss patients (1/56=1.8%). The present analysis did not agree with the concept that the 961delT mutation causes aminoglycoside-induced hearing loss.
为检测被认为与氨基糖苷类药物所致听力损失相关的961delT线粒体点突变的频率,对以下两组人群进行了限制性片段长度多态性(RFLP)分析:(1)334例无亲缘关系的感音神经性听力损失(SNHL)患者;(2)56例有氨基糖苷类抗生素注射史的患者。约2%的SNHL患者存在961delT突变,这提示该突变在听力受损人群中的患病率可能相对较高。然而,以下发现对该突变是否真的与听力损失相关提出了质疑:(1)在对照受试者中发现了相似的频率;(2)听力损失在家族中未呈分离状态;(3)异质性率和衰老与听力损失的严重程度无关;(4)在氨基糖苷类药物所致听力损失患者中的患病率较低(1/56 = 1.8%)。本分析结果与961delT突变导致氨基糖苷类药物所致听力损失这一概念不符。